Vladimír Džavík
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Vladimír Džavík has a total of 247 co-authors. Here are the top co-authors by number of shared publications:
Christopher B. Overgaard
Harold and Esther Mecklinger Family and the Posluns Family Cardiac Catheterization Research Laboratory, Mount Sinai Hospital, Toronto, ON, Canada (C.B.O., W.C., S.C., R.W., J.S.F.).
15 shared publicationsWilliam Chan
Peter Munk Cardiac Centre, Toronto General Hospital, University Health Network, Toronto, Canada
7 shared publications- Ashish H. Shah
Section of Cardiology, Department of Internal Medicine, Max Rady College of Medicine, University of Manitoba, Winnipeg, MB, Canada
6 shared publications Douglas Ing
Division of Cardiology, Peter Munk Cardiac Centre, University Health Network, Toronto, Ontario, Canada
6 shared publications- Eric Horlick
Toronto Congenital Cardiac Centre for Adults, Peter Munk Cardiac Centre, University Health Network, Toronto, Ontario, Canada
6 shared publications Joan Ivanov
Division of Cardiology, Peter Munk Cardiac Centre, University Health Network, Toronto, Ontario, Canada; Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada
6 shared publications
Latest Publications
- Open Access
- 11 June 2025
- Published by Elsevier in JACC: Case Reports
- Vol. 30 (14) , 103684
Life-Threatening Dynamic Coronary Obstruction in a Patient With Rhabdomyosarcoma Treated With Stenting
- 11 June 2025
- Published by Elsevier in JACC: Case Reports
- Vol. 30 (14) , 103684
Open AccessLife-Threatening Dynamic Coronary Obstruction in a Patient With Rhabdomyosarcoma Treated With Stenting
- Open Access
- 9 April 2025
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 18 (9) , 1194-1196
The D Crush
- 9 April 2025
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 18 (9) , 1194-1196
Open AccessThe D Crush
- Open Access
- 19 January 2025
- Published by Elsevier in Canadian Journal of Cardiology
- Vol. 41 (4) , 771-774
The Present Status of the Intra-aortic Balloon Pump for Circulatory Support in Patients With Cardiogenic Shock and High-risk Percutaneous Coronary Intervention
- 19 January 2025
- Published by Elsevier in Canadian Journal of Cardiology
- Vol. 41 (4) , 771-774
Open AccessThe Present Status of the Intra-aortic Balloon Pump for Circulatory Support in Patients With Cardiogenic Shock and High-risk Percutaneous Coronary Intervention
- 1 September 2024
- Published by Wolters Kluwer Health in Hypertension
- Vol. 81 (9) , 1996-2005
Coronary and Systemic Vasodilator Responsiveness of Patients Receiving Conventional Intermittent or Nocturnal Hemodialysis
BACKGROUND: Nocturnal hemodialysis (nHD) restores the attenuated brachial artery vasodilator responsiveness of patients receiving conventional intermittent hemodialysis (iHD). Its impact on coronary vasodilatation is unknown. METHODS: We evaluated 25 patients on hemodialysis who fulfilled transplant criteria: 15 on iHD (4-hour sessions, 3 d/wk) and 10 on nHD (≈40 h/wk over 8–10-hour sessions) plus 6 control participants. Following diagnostic angiography, left anterior descending (LAD) coronary flow reserve and mean luminal diameter were quantified at baseline and during sequential intracoronary administration of adenosine (infusion and bolus), nitroglycerin (bolus), acetylcholine (infusion), acetylcholine coinfused with vitamin C, and, finally, sublingual nitroglycerin. RESULTS: Coronary flow reserve in those receiving nHD was augmented relative to iHD (3.28±0.26 versus 2.17±0.12 [mean±SEM]; P P =0.011). Luminal dilatations induced by intracoronary adenosine and nitroglycerin were similar in nHD and controls but blunted in the iHD cohort ( P P P <0.05, all comparisons). CONCLUSIONS: Coronary and systemic vasodilator responsiveness to both adenosine and nitroglycerin is augmented in patients receiving nHD relative to those receiving iHD, whereas vasoconstrictor responsiveness to acetylcholine does not differ. By improving coronary conduit and microvascular function, nHD may reduce the cardiovascular risk of patients on dialysis.
- 1 September 2024
- Published by Wolters Kluwer Health in Hypertension
- Vol. 81 (9) , 1996-2005
Coronary and Systemic Vasodilator Responsiveness of Patients Receiving Conventional Intermittent or Nocturnal Hemodialysis
BACKGROUND: Nocturnal hemodialysis (nHD) restores the attenuated brachial artery vasodilator responsiveness of patients receiving conventional intermittent hemodialysis (iHD). Its impact on coronary vasodilatation is unknown. METHODS: We evaluated 25 patients on hemodialysis who fulfilled transplant criteria: 15 on iHD (4-hour sessions, 3 d/wk) and 10 on nHD (≈40 h/wk over 8–10-hour sessions) plus 6 control participants. Following diagnostic angiography, left anterior descending (LAD) coronary flow reserve and mean luminal diameter were quantified at baseline and during sequential intracoronary administration of adenosine (infusion and bolus), nitroglycerin (bolus), acetylcholine (infusion), acetylcholine coinfused with vitamin C, and, finally, sublingual nitroglycerin. RESULTS: Coronary flow reserve in those receiving nHD was augmented relative to iHD (3.28±0.26 versus 2.17±0.12 [mean±SEM]; P P =0.011). Luminal dilatations induced by intracoronary adenosine and nitroglycerin were similar in nHD and controls but blunted in the iHD cohort ( P P P <0.05, all comparisons). CONCLUSIONS: Coronary and systemic vasodilator responsiveness to both adenosine and nitroglycerin is augmented in patients receiving nHD relative to those receiving iHD, whereas vasoconstrictor responsiveness to acetylcholine does not differ. By improving coronary conduit and microvascular function, nHD may reduce the cardiovascular risk of patients on dialysis.
- 24 March 2024
- Published by Elsevier in Canadian Journal of Cardiology
- Vol. 40 (9) , 1632-1634
A Left Main Bifurcation Risk Score: Can It Safely Guide Our Choice of Bifurcation Stenting Technique?
- 24 March 2024
- Published by Elsevier in Canadian Journal of Cardiology
- Vol. 40 (9) , 1632-1634
A Left Main Bifurcation Risk Score: Can It Safely Guide Our Choice of Bifurcation Stenting Technique?
- 22 November 2023
- Published by Elsevier in JACC: Cardiovascular Imaging
- Vol. 17 (6) , 642-655
Cardiac PET Myocardial Blood Flow Quantification Assessment of Early Cardiac Allograft Vasculopathy
- 22 November 2023
- Published by Elsevier in JACC: Cardiovascular Imaging
- Vol. 17 (6) , 642-655
Cardiac PET Myocardial Blood Flow Quantification Assessment of Early Cardiac Allograft Vasculopathy
- 1 June 2023
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 16 (6) , e010173
Fibrotic Plaque and Microvascular Dysfunction Predict Early Cardiac Allograft Vasculopathy Progression After Heart Transplantation: The Early Post Transplant Cardiac Allograft Vasculopathy Study
Background: Early cardiac allograft vasculopathy (CAV) prognostication is needed to improve long-term outcomes after heart transplantation. We characterized first year posttransplant coronary anatomic-physiologic alterations to determine predictors of early CAV progression.Methods: Heart transplant recipients at 2 institutions (enrolled January 2018 to March 2021) underwent prospective evaluation 3 and 12-month posttransplant with angiography and left anterior descending artery intravascular ultrasound, optical coherence tomography, fractional flow reserve, coronary flow reserve, and index of microcirculatory resistance measurements. CAV progression was assessed by intravascular ultrasound change in percentage intimal volume from baseline to 12-month follow-up.Results: Eighty-two patients (mean age, 51 years; 60% men) completed evaluation at mean 13.8 and 56.3 weeks posttransplant. Donor atherosclerosis (baseline intravascular ultrasound maximal intimal thickness, = 0.5 mm) was evident in 50%. De novo (follow-up maximal intimal thickness, = 0.5 mm) and rapidly progressive CAV (maximal intimal thickness, = 0.5-mm increase from baseline) developed in 24% and 13%, respectively. On optical coherence tomography, baseline to follow-up median intimal volume increased 42% (0.58 mm(3)/mm), percentage intimal volume increased 44% (4.6%), vessel volume decreased 4% (-0.50 mm(3)/mm) and lumen volume decreased 9% (-1.02 mm(3)/mm); P<0.05 for all. Fibrotic plaque was the predominant morphology: baseline, 29% and follow-up, 50%. Coronary physiology was abnormal in 41% at baseline and 45% at follow-up, with 1 in 5 patients having microvascular dysfunction (index of microcirculatory resistance, = 25). On multivariable linear regression analysis, recipient male sex, fibrotic plaque, and index of microcirculatory resistance were independent predictors of coronary disease progression.Conclusions: Fibrotic plaque on optical coherence tomography and index of microcirculatory resistance early posttransplant predict CAV progression in the first year of transplantation.Registration:URL: ; Unique identifier: NCT03217786.
- 1 June 2023
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 16 (6) , e010173
Fibrotic Plaque and Microvascular Dysfunction Predict Early Cardiac Allograft Vasculopathy Progression After Heart Transplantation: The Early Post Transplant Cardiac Allograft Vasculopathy Study
Background: Early cardiac allograft vasculopathy (CAV) prognostication is needed to improve long-term outcomes after heart transplantation. We characterized first year posttransplant coronary anatomic-physiologic alterations to determine predictors of early CAV progression.Methods: Heart transplant recipients at 2 institutions (enrolled January 2018 to March 2021) underwent prospective evaluation 3 and 12-month posttransplant with angiography and left anterior descending artery intravascular ultrasound, optical coherence tomography, fractional flow reserve, coronary flow reserve, and index of microcirculatory resistance measurements. CAV progression was assessed by intravascular ultrasound change in percentage intimal volume from baseline to 12-month follow-up.Results: Eighty-two patients (mean age, 51 years; 60% men) completed evaluation at mean 13.8 and 56.3 weeks posttransplant. Donor atherosclerosis (baseline intravascular ultrasound maximal intimal thickness, = 0.5 mm) was evident in 50%. De novo (follow-up maximal intimal thickness, = 0.5 mm) and rapidly progressive CAV (maximal intimal thickness, = 0.5-mm increase from baseline) developed in 24% and 13%, respectively. On optical coherence tomography, baseline to follow-up median intimal volume increased 42% (0.58 mm(3)/mm), percentage intimal volume increased 44% (4.6%), vessel volume decreased 4% (-0.50 mm(3)/mm) and lumen volume decreased 9% (-1.02 mm(3)/mm); P<0.05 for all. Fibrotic plaque was the predominant morphology: baseline, 29% and follow-up, 50%. Coronary physiology was abnormal in 41% at baseline and 45% at follow-up, with 1 in 5 patients having microvascular dysfunction (index of microcirculatory resistance, = 25). On multivariable linear regression analysis, recipient male sex, fibrotic plaque, and index of microcirculatory resistance were independent predictors of coronary disease progression.Conclusions: Fibrotic plaque on optical coherence tomography and index of microcirculatory resistance early posttransplant predict CAV progression in the first year of transplantation.Registration:URL: ; Unique identifier: NCT03217786.
- Open Access
- 26 May 2023
- Published by Elsevier in JACC: Advances
- Vol. 2 (3) , 100357
Cardiogenic Shock a Quarter Century Later
- 26 May 2023
- Published by Elsevier in JACC: Advances
- Vol. 2 (3) , 100357
Open AccessCardiogenic Shock a Quarter Century Later
- 1 May 2022
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 15 (5) , 406-414
Prognostic Role of Residual Thrombus Burden Following Thrombectomy: Insights From the TOTAL Trial
Background: It is unclear whether more effective forms of thrombus removal than current aspiration catheters would lead to improved outcomes. We sought to evaluate the prognostic role of residual thrombus burden (rTB), after manual thrombectomy, in patients undergoing primary percutaneous coronary intervention with routine manual thrombectomy in the TOTAL trial (Thrombectomy Versus PCI Alone). Methods: This is a single-arm analysis of patients from the TOTAL trial who underwent routine manual aspiration thrombectomy. The rTB was quantified by an angiographic core laboratory using the Thrombolysis in Myocardial Infarction criteria and validated using existing optical coherent tomography data. Large rTB was defined as grade ≥3. The primary outcome was death from cardiovascular causes, recurrent myocardial infarction, cardiogenic shock, or new or worsening heart failure within 180 days. Results: Of 5033 patients randomized to routine thrombectomy, 2869 patients had quantifiable rTB (1014 [35%] had large rTB). Patients with large rTB were more likely to have hypertension, previous percutaneous coronary intervention, myocardial infarction, or Killip class III on presentation but less likely to have Killip class I. The primary outcome occurred more frequently in patients with large rTB, even after adjustment for known risk predictors (8.6% versus 4.6%; adjusted hazard ratio, 1.83 [95% CI, 1.34–2.48]). These patients also had a higher risk of cardiovascular death (adjusted hazard ratio, 1.83 [95% CI, 1.13–2.95]), cardiogenic shock (adjusted hazard ratio, 2.02 [95% CI, 1.08–3.76]), and heart failure (adjusted hazard ratio, 1.74 [95% CI, 1.02–2.96]) but not myocardial infarction or stroke. Conclusions: Large rTB is a common finding in primary percutaneous coronary intervention and is associated with increased risk of adverse cardiovascular outcomes, including cardiovascular death. Future technologies offering better thrombus removal than current devices may decrease or even eliminate the risk associated with rTB. This, potentially, can turn into a strategic option to be studied in clinical trials. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01149044.
- 1 May 2022
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 15 (5) , 406-414
Prognostic Role of Residual Thrombus Burden Following Thrombectomy: Insights From the TOTAL Trial
Background: It is unclear whether more effective forms of thrombus removal than current aspiration catheters would lead to improved outcomes. We sought to evaluate the prognostic role of residual thrombus burden (rTB), after manual thrombectomy, in patients undergoing primary percutaneous coronary intervention with routine manual thrombectomy in the TOTAL trial (Thrombectomy Versus PCI Alone). Methods: This is a single-arm analysis of patients from the TOTAL trial who underwent routine manual aspiration thrombectomy. The rTB was quantified by an angiographic core laboratory using the Thrombolysis in Myocardial Infarction criteria and validated using existing optical coherent tomography data. Large rTB was defined as grade ≥3. The primary outcome was death from cardiovascular causes, recurrent myocardial infarction, cardiogenic shock, or new or worsening heart failure within 180 days. Results: Of 5033 patients randomized to routine thrombectomy, 2869 patients had quantifiable rTB (1014 [35%] had large rTB). Patients with large rTB were more likely to have hypertension, previous percutaneous coronary intervention, myocardial infarction, or Killip class III on presentation but less likely to have Killip class I. The primary outcome occurred more frequently in patients with large rTB, even after adjustment for known risk predictors (8.6% versus 4.6%; adjusted hazard ratio, 1.83 [95% CI, 1.34–2.48]). These patients also had a higher risk of cardiovascular death (adjusted hazard ratio, 1.83 [95% CI, 1.13–2.95]), cardiogenic shock (adjusted hazard ratio, 2.02 [95% CI, 1.08–3.76]), and heart failure (adjusted hazard ratio, 1.74 [95% CI, 1.02–2.96]) but not myocardial infarction or stroke. Conclusions: Large rTB is a common finding in primary percutaneous coronary intervention and is associated with increased risk of adverse cardiovascular outcomes, including cardiovascular death. Future technologies offering better thrombus removal than current devices may decrease or even eliminate the risk associated with rTB. This, potentially, can turn into a strategic option to be studied in clinical trials. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01149044.
- 16 March 2022
- Published by Elsevier in American Heart Journal
- Vol. 249, 45-56
Double-blind, placebo-controlled evaluation of biorest liposomal alendronate in diabetic patients undergoing PCI: The BLADE-PCI trial
- 16 March 2022
- Published by Elsevier in American Heart Journal
- Vol. 249, 45-56
Double-blind, placebo-controlled evaluation of biorest liposomal alendronate in diabetic patients undergoing PCI: The BLADE-PCI trial